Combination drug development in BRAF mutant colorectal cancer

Oncoscience. 2018 Apr 29;5(3-4):51-53. doi: 10.18632/oncoscience.399. eCollection 2018 Mar.

Authors

Michael Lam¹, Shubham Pant¹, Timothy A Yap¹

Affiliation

¹ Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), and the Department of Thoracic/Head and Neck Medical Oncology; Khalifa Institute for Personalized Cancer Therapy;The Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 455, Houston, Texas 77030, USA.

No abstract available

Keywords: BRAF mutant colorectal cancer; ERK; MEK; combinations; resistance.

Publication types

Editorial